The landscape of public health in India is marked by a high burden of vector-borne diseases (VBDs), which are a major cause of morbidity and mortality. This article aims to provide a comprehensive review of the prevalence and management of VBDs in India, focusing on diseases such as malaria, dengue, and chikungunya.
India carries a significant burden of VBDs. Malaria, for instance, is endemic in most of the country, with rural and tribal areas being the most affected. Dengue, on the other hand, has emerged as a major public health concern over the last few decades, with urban and semi-urban areas witnessing a surge in cases. Chikungunya, although less prevalent than malaria and dengue, has caused significant outbreaks in several states.
The management of VBDs in India involves a multipronged strategy that includes prevention, early detection, and treatment. Prevention strategies primarily involve vector control measures, such as the use of insecticide-treated nets and indoor residual spraying. Early diagnosis and prompt treatment are crucial for reducing morbidity and preventing complications. The National Vector Borne Disease Control Programme (NVBDCP) plays a pivotal role in the management of VBDs in India, providing guidelines and resources for prevention, diagnosis, and treatment.
The management of VBDs in India faces several challenges, including a lack of awareness, inadequate healthcare infrastructure, and resistance to insecticides. Future efforts should focus on strengthening disease surveillance, improving diagnostic facilities, and enhancing community participation in vector control activities. Research into new vector control methods and treatments is also crucial.
Understanding the prevalence and management of VBDs is critical for healthcare professionals in India. Despite the challenges, significant progress has been made in controlling these diseases. However, sustained efforts are required to further reduce the burden of VBDs and improve public health in India.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation